Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PEACEHEALTH

NPI: 1487917233 · FRIDAY HARBOR, WA 98250 · Critical Access Hospital · NPI assigned 06/18/2012

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official SEIRER, JEFFREY controls 14+ related entities in our dataset. Read more

$1.06M
Total Medicaid Paid
47,188
Total Claims
39,067
Beneficiaries
63
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialSEIRER, JEFFREY (SYS VP FIN INTEGRITY/CONTROLLER)
NPI Enumeration Date06/18/2012

Related Entities

Other providers sharing the same authorized official: SEIRER, JEFFREY

ProviderCityStateTotal Paid
PEACEHEALTH VANCOUVER WA $81.65M
PEACEHEALTH LONGVIEW WA $48.29M
PEACEHEALTH BELLINGHAM WA $47.27M
PEACEHEALTH SPRINGFIELD OR $30.72M
PEACEHEALTH EUGENE OR $13.35M
PEACEHEALTH VANCOUVER WA $2.56M
PEACEHEALTH EUGENE OR $1.84M
PEACEHEALTH VANCOUVER WA $1.00M
PEACEHEALTH VANCOUVER WA $814K
PEACEHEALTH SPRINGFIELD OR $395K
PEACEHEALTH BELLINGHAM WA $77K
PEACEHEALTH KELSO WA $13K
PEACEHEALTH KETCHIKAN AK $9K
PEACEHEALTH EUGENE OR $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 5,738 $126K
2019 5,214 $108K
2020 5,018 $109K
2021 6,901 $174K
2022 9,298 $222K
2023 9,217 $197K
2024 5,802 $126K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99283 Emergency department visit for the evaluation and management, moderate severity 3,089 2,743 $325K
96361 Intravenous infusion, hydration; each additional hour 778 633 $221K
99284 Emergency department visit for the evaluation and management, high severity 2,485 2,004 $161K
99285 Emergency department visit for the evaluation and management, high severity with immediate threat to life 2,400 1,767 $98K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1,745 1,623 $45K
87631 445 418 $29K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 452 306 $27K
80053 Comprehensive metabolic panel 4,475 3,762 $21K
99282 Emergency department visit for the evaluation and management, low to moderate severity 186 172 $20K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 3,167 1,898 $18K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 171 167 $13K
36415 Collection of venous blood by venipuncture 5,589 4,774 $12K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 483 218 $10K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1,412 914 $8K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 4,805 4,009 $8K
84443 Thyroid stimulating hormone (TSH) 1,328 1,282 $7K
71046 Radiologic examination, chest; 2 views 727 666 $6K
80048 Basic metabolic panel (calcium, ionized) 1,021 944 $4K
70450 Computed tomography, head or brain; without contrast material 26 24 $3K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 57 53 $3K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 266 249 $3K
84484 923 688 $3K
80061 Lipid panel 735 726 $2K
83605 305 255 $2K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1,547 1,310 $2K
74177 Computed tomography, abdomen and pelvis; with contrast material 14 14 $1K
84703 598 560 $1K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 955 840 $1K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 14 13 $1K
83036 Hemoglobin; glycosylated (A1C) 360 357 $1K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml 424 392 $1K
81001 1,570 1,427 $1K
96375 Therapeutic injection; each additional sequential IV push 1,059 837 $879.02
80047 166 146 $807.69
86803 116 111 $518.63
83735 1,067 890 $433.24
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 99 97 $422.69
85027 141 120 $404.24
77063 Screening digital breast tomosynthesis, bilateral 12 12 $304.20
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 120 102 $159.35
77067 Screening mammography, bilateral, including computer-aided detection 12 12 $152.10
J1885 Injection, ketorolac tromethamine, per 15 mg 135 120 $83.95
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 273 162 $78.05
80305 163 143 $75.83
85014 157 138 $75.73
85610 115 91 $74.72
83690 281 248 $60.51
81003 98 92 $52.85
85652 52 48 $51.43
83550 13 12 $47.47
86140 14 13 $41.97
87086 Culture, bacterial; quantitative colony count, urine 17 15 $37.20
83540 13 12 $28.36
90686 12 12 $24.52
87581 14 13 $24.49
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 29 27 $21.11
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 15 14 $12.25
A9270 Non-covered item or service 60 37 $0.00
G0008 Administration of influenza virus vaccine 28 28 $0.00
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 17 16 $0.00
80306 15 13 $0.00
J2405 Injection, ondansetron hydrochloride, per 1 mg 227 192 $0.00
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) 96 86 $0.00